AffyImmune to Present CAR T Therapy AIC100 Data at AACR 2025 Conference
AffyImmune Announces Plenary Presentation for AIC100
AffyImmune Therapeutics, Inc., a pioneering biopharmaceutical firm currently in the clinical development phase, has made a significant announcement regarding the upcoming presentation of its prominent CAR T therapy, AIC100. The presentation is scheduled to take place at the prestigious American Association for Cancer Research (AACR) Annual Meeting, which will run from April 25 to April 30, 2025. This important event will be hosted at the McCormick Place Convention Center in Chicago, Illinois.
Significance of AIC100
AIC100 is an affinity-tuned CAR T therapy specifically designed to target the ICAM-1 antigen, primarily focusing on providing treatment for patients suffering from advanced thyroid cancer, a condition that currently lacks effective treatment options. This innovative therapy has the potential to address various challenges associated with CAR T therapies, including toxicity, antigen loss, T-cell exhaustion, and difficulties in T-cell trafficking, while also enabling in vivo tracking of CAR T cells.
Presentation Details
The presentation, which promises to provide groundbreaking insights, will feature the results from a Phase 1 study that evaluates both the safety and efficacy of AIC100 in patients with advanced thyroid cancers. AffyImmune's CEO, Daniel Janse, expressed the company's enthusiasm about showcasing the updated Phase 1 data at AACR and providing interim results from their ongoing Phase 1 Dose Escalation trial.
Key Presentation Information:
- - Title: ICAM-1 Directed Chimeric Antigen Receptor (CAR) T Cells (AIC100) in Patients with Advanced Thyroid Cancers - Clinical and Translational Data from the Phase 1 Dose Escalation Study
- - Presenter: Dr. Samer Ali Srour, University of Texas MD Anderson Cancer Center
- - Session Type: Oral Presentation – Clinical Trials Plenary Session
- - Abstract Number: CT206
- - Date and Time: April 29, 2025, from 10:15 AM to 12:15 PM CST
- - Location: McCormick Place Convention Center, Chicago, Illinois
About AffyImmune Therapeutics
AffyImmune Therapeutics stands at the forefront of developing innovative CAR T cell therapies that aim to transform treatment modalities for cancer. With their proprietary technology harnessing the ICAM-1/LFA-1 interaction, they are addressing critical challenges in CAR T therapies. Their primary candidate, AIC100, highlights the company's commitment to improve treatment options for oncologic patients with high unmet medical needs. AffyImmune is based in Natick, Massachusetts, and is resolute in its mission to advance patient care through revolutionary therapeutic approaches.
For additional information and updates, please visit AffyImmune's official website.
In anticipation of the AACR 2025 conference, experts in the field are looking forward to seeing how AIC100 may play a pivotal role in the future of cancer therapies. This presentation represents not only a step forward for AffyImmune but also a beacon of hope for patients battling advanced thyroid cancers.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.